KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Pragmatic monitoring of emerging efficacy data in randomized controlled trials.

Shrikant I Bangdiwala, Salim Yusuf

Clin Trials 22(2) 155-160

PMID39520228
PMCIDPMC11986074
DOI10.1177/17407745241290729
发表日期2024-11-09
摘要

摘要

Monitoring the conduct of phase III randomized controlled trials is driven by ethical reasons to protect the study integrity and the safety of trial participants. We propose a group sequential, pragmatic approach for monitoring the accumulating efficacy information in randomized controlled trials. The "Population Health Research Institute boundary" is simple to implement and sensible, as it considers the reduction in uncertainty with increasing information as the study progresses. It is also pragmatic, since it takes into consideration the typical monitoring behavior of monitoring committees of large multicenter trials and is relatively easily implemented. It not only controls the overall Lan-DeMets type I error probability (alpha) spent, but performs better than other group sequential boundaries for the total nominal study alpha. We illustrate the use of our monitoring approach in the early termination of two past completed trials.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。